Palliative treatment of painful osseous metastases in prostate carcinoma with the osteotropic β-emitter rhenium-186-HEDP;Palliative Schmerztherpaie beim ossar metastasierten Prostatakarzinom mit dem osteotropen β-Strahler 186Rhenium-Hydroxyethylidendiphosphonat (HEDP)

Urologe - Ausgabe A

Volumn 36, Issue 6, 1997, Pages 540-547

  Holle, L H ^a,b   Humke, U ^a   Trampert, L ^a   Ziegler, M ^a   Kirsch, C M ^a   Oberhausen, E ^a  

^a SAARLAND UNIVERSITY   (Germany)

^b Abteilung fur Nuklearmedizin   (Germany)

Author keywords

Bone metastases; Painrelief; Prostate cancer; Rhenium 186 HEDP; Strontium 89

Indexed keywords

ETIDRONIC ACID RE 186; BISPHOSPHONIC ACID DERIVATIVE; DIAGNOSTIC AGENT; ETIDRONIC ACID; ORGANOMETALLIC COMPOUND; RADIOPHARMACEUTICAL AGENT; RHENIUM; RHENIUM-186 HEDP; TECHNETIUM COMPLEX; TECHNETIUM TC 99M 1,1 DIPHOSPHONOPROPANE 2,3 DICARBOXYLIC ACID; TECHNETIUM TC 99M 1,1-DIPHOSPHONOPROPANE-2,3-DICARBOXYLIC ACID;

ARTICLE; BONE CANCER; BONE METASTASIS; BONE PAIN; CANCER PAIN; CANCER PALLIATIVE THERAPY; CANCER PATIENT; HUMAN; MALE; PROSTATE CARCINOMA; AGED; BONE TUMOR; METASTASIS; MIDDLE AGED; PAIN; PALLIATIVE THERAPY; PATHOLOGY; PATHOPHYSIOLOGY; PROSTATE TUMOR; RADIOTHERAPY; SCINTISCANNING;

AGED; AGED, 80 AND OVER; BONE NEOPLASMS; DIPHOSPHONATES; ETIDRONIC ACID; HUMANS; MALE; MIDDLE AGED; ORGANOMETALLIC COMPOUNDS; ORGANOTECHNETIUM COMPOUNDS; PAIN; PALLIATIVE CARE; PROSTATIC NEOPLASMS; RADIOPHARMACEUTICALS; RADIOTHERAPY; RHENIUM;

EID: 0031282695     PISSN: 03402592     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001200050134     Document Type: Article

References (19)

1. Ahles TA, Ruckdeschel JC, Blanchard EB (1984) Cancerrelated pain II assessment with visual analogue scales. J Psychosom Res 28: 121-124
2. Blake GM, Zivanovic MA, Blaquiere RM, Fine DR, McEwan AJ, Ackery DM (1988) Strontium-89 therapy: measurement of absorbed dose to skeletal metastases. J Nucl Med 29: 549-557
3. Blake GM, Zivanovic MA, McEwan AJ, Ackery DM (1986) Strontium-89 therapy: strontium kinetics in disseminated carcinoma of the prostate. Eur J Nucl Med 12: 447-454
4. Buchali K, Correns H-J, Schuerer M, Schnorr D, Lips H, Sydow K (1988) Results of a double blind study of 89-Strontium therapy of skeletal metastases of prostatic carcinoma. Eur J Nucl Med 14: 349-351
5. De Klerk JMH, van Dijk A, van het Schip AD, Zonnenberg BA, van Rijk PP (1992) Pharmacokinetics of Rhenium-186 after administration of 186-Rhenium-HEDP to patients with bone meastases. J Nucl Med 33: 646-651
6. De Klerk JMH, van het Schip AD, Zonnenberg BA et al. (1994) Evaluation of thrombozytopenia in patients treated with Rhenium-186-HEDP: guidelines for individual dosage recommodations. J Nucl Med 35: 1423-1428
7. Englaro EE, Schroder LE, Thomas SR, Williams CC, Maxon HR (1992) Safety and efficacy of repeated wequential administration of Re-186(Sn)HEDP as pallaitive therapy for painful skeletalmetastases. Clin Nucl Med 17: 41-44
8. Fossa SD, Aaronson NK, Newling D, van Cangh PJ, Denis L, Kurth K-H, de Pauw M and the members of the EORTC GU Group (1990) Subjective response to treatment of hormone-resistant metastatic prostatic cancer. Eur J Cancer Clin Oncol 26: 1133-1136
9. Laing AH, Ackery DM, Bayly RJ et al. (1991) Strontium-89 chloride for pain palliation in prostatic skeletal malignancy. Br J Radiol 64: 816-822
10. Lewington VL (1993) Targeted radionuclide therapy for bone metastases. Eur J Nucl Med 20: 66-74
11. Maxon III HR, Schroder LE, Hertzberg VS et al. (1991) Rhenium-186(Sn)HEDP for treatment of painful osseous metastases: results of a double-blind crossover comparison with placebo. J Nucl Med 32: 1877-1881
12. Maxon III HR, Schroder LE, Thomas SR (1990) Rhenium-186(Sn)HEDP for treatment of painful osseous metastases: initial clinical experience in 20 patients with hormone resistant prostate cancer. Radiology 176: 155-159
13. Maxon III HR, Deutsch EA, Thomas SR, Libson K, Lukes SJ, Williams CC, Seham A (1988) Re-186(Sn)HEDP for treatment of multiple foci in bone: human biodistribution and dosimetric studies. Radiology 166: 501-507
14. Palmedo H, Bender H, Schomburg A et al. (1996) Schmerztherapie mit Rhenium-186 HEDP bei multiplen Knochenmetastasen (Therapy with Rhenium-186-HEDP in painful bone metastases). Nucl Med 35: 63-67
15. Quirinen JM, Han SH, Zonnenberg BA et al. (1996) Efficacy of rhenium-186-etidronate in prostatic cancer patients with metastatic bone pain. J Nucl Med 37: 1511-1515
16. Robinson RG, Spicer JA, Preston DF, Wegst AV, Norman LM (1987) Treatment of metastatic bone pain with Strontium-89. Nucl Med Biol 14: 219-222
17. Sternberg CN, Ianari A (1996) Hormone refractory prostate cancer. Curr Opinion Urol 6: 258-263
18. Tannock I, Gospodarowicz M, Meakin W, Panzarella T, Stewart L, Rider W (1989) Treatment of metastatic cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response. J Clin Oncol 7: 590-597
19. Zonnenberg BA, De Klerk JMH, Van Rijk PP et al. (1991) 186-Re-HEDP for treatment of painful bone metastases in patients with metastatic prostate or breast cancer. J Nucl Med 32: 1082 (abstr)